06 Jul 2017
N+1 Singer - EKF Diagnostics - Positive trading in Q2 prompts further upgrades
The positive trading experienced in Q1 has continued into Q2, with EKF now expecting 2017 adj. EBITDA to be comfortably ahead of market expectations. We upgrade our EBITDA forecasts (after upgrading 2017 and 2018 EBITDA by 7-8% in May) by 9-10%. EKF has clearly had a strong H1 2017 and we believe the momentum will continue in H2 and beyond.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - EKF Diagnostics - Positive trading in Q2 prompts further upgrades
EKF Diagnostics Holdings plc (EKF:LON) | 26.8 0 0.0% | Mkt Cap: 121.6m
- Published:
06 Jul 2017 -
Author:
Chris Glasper -
Pages:
3
The positive trading experienced in Q1 has continued into Q2, with EKF now expecting 2017 adj. EBITDA to be comfortably ahead of market expectations. We upgrade our EBITDA forecasts (after upgrading 2017 and 2018 EBITDA by 7-8% in May) by 9-10%. EKF has clearly had a strong H1 2017 and we believe the momentum will continue in H2 and beyond.